These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 15273334)

  • 21. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
    Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
    AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
    Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
    Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
    Yun M; Choi HS; Yoo E; Bong JK; Ryu YH; Lee JD
    J Nucl Med; 2005 Jun; 46(6):953-7. PubMed ID: 15937305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
    Schaffler GJ; Wolf G; Schoellnast H; Groell R; Maier A; Smolle-Jüttner FM; Woltsche M; Fasching G; Nicoletti R; Aigner RM
    Radiology; 2004 Jun; 231(3):858-65. PubMed ID: 15105451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of fusion images using (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography in local recurrence of rectal cancer.
    Fukunaga H; Sekimoto M; Tatsumi M; Ikenaga M; Ohue M; Seshimo I; Higuchi I; Takayama O; Yasui M; Ikeda M; Yamamoto H; Monden M
    Int J Oncol; 2002 Apr; 20(4):691-5. PubMed ID: 11894111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnosis of the postoperative local recurrence of rectal cancer by FDG-PET--a case report].
    Katsumoto Y; Maruyama N; Nakamura M; Shingai T; Maruyama K; Nakaguchi K; Furukawa J; Okajima S; Sue F; Fukunaga H; Ikenaga M; Sekimoto K
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1688-91. PubMed ID: 11708010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?
    Yang Z; Cheng J; Pan L; Hu S; Xu J; Zhang Y; Wang M; Zhang J; Ye D; Zhang Y
    Ann Nucl Med; 2012 Aug; 26(7):571-7. PubMed ID: 22763630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.
    Bar-Shalom R; Yefremov N; Guralnik L; Gaitini D; Frenkel A; Kuten A; Altman H; Keidar Z; Israel O
    J Nucl Med; 2003 Aug; 44(8):1200-9. PubMed ID: 12902408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of
    Sawicki LM; Kirchner J; Grueneisen J; Ruhlmann V; Aktas B; Schaarschmidt BM; Forsting M; Herrmann K; Antoch G; Umutlu L
    Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):622-629. PubMed ID: 29164299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work?
    Saleh Farghaly HR; Mohamed Sayed MH; Nasr HA; Abdelaziz Maklad AM
    Indian J Nucl Med; 2015; 30(4):314-9. PubMed ID: 26430314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer.
    Gearhart SL; Frassica D; Rosen R; Choti M; Schulick R; Wahl R
    Ann Surg Oncol; 2006 Mar; 13(3):397-404. PubMed ID: 16485158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
    Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.